Journal of Medical Academics

Register      Login

VOLUME 1 , ISSUE 1 ( January-June, 2018 ) > List of Articles

REVIEW ARTICLE

Resistance to Ciprofloxacin in Urinary Tract Infection

Salma Malik, Adesh G Mathur, M Fadil Salmani

Keywords : Gram-negative bacteria, Urinary tract infection,Ciprofloxacin resistance

Citation Information : Malik S, Mathur AG, Salmani MF. Resistance to Ciprofloxacin in Urinary Tract Infection. Journal of Medical Academics 2018; 1 (1):50-52.

DOI: 10.5005/jp-journals-10070-0009

License: CC BY-ND 3.0

Published Online: 00-06-2018

Copyright Statement:  Copyright © 2018; Jaypee Brothers Medical Publishers (P) Ltd.


Abstract

Introduction: Urinary tract infections (UTIs) are one of the most common infectious diseases worldwide. Approximately >50% of women at least once in their lifetime have suffered from UTI and received antibiotic treatment. Serious UTIs are difficult to treat as it involves a wide array of Gram-positive as well as Gram-negative bacteria. Escherichia coli (E. coli) is the primary causative agent implicated in >80% of UTI cases. Current approach to treatment: A variety of drugs are indicated for the treatment of various clinical forms of UTI. These include nitrofurantoin, cotrimoxazole, fluoroquinolones, some cephalosporins, piperacillin-tazobactam, meropenem, ertapenem etc. Recently various studies have reported ciprofloxacin resistance among E. coli, the most common uropathogen. Review of literature pertaining to ciprofloxacin resistance: The prevalence, factors contributing to resistance and mechanism thereof have been reviewed. Hence, it is necessary to rationalize the use of ciprofloxacin to control the threat of antibiotic resistance. Conclusion: The incidence of resistance to ciprofloxacin has increased steadily during the past few years. Thus, the empirical use of fluoroquinolones for treatment of UTI should be reconsidered and the drug used only whenthere are clear laboratory tests confirming sensitivity to the drug.


PDF Share
  1. Fasugba O, Gardner A, Mitchell BG, Mnatzaganian G. Ciprofloxacin resistance in community- and hospital-acquired Escherichia coli urinary tract infections: a systematic review and meta-analysis of observational studies. BMC Infect Dis. 2015;15:545.
  2. Gururaju T, Sarojamma V, Ramakrishna V. Prevalence and Fluoroquinolone Resistance Pattern in Escherichia coli Isolates of Urinary Tract Infection (UTI) Patients. JKIMSU. 2015 Apr- June;4(2):56-64.
  3. Rowe TA, Juthani-Mehta M. Diagnosis and management of urinary tract infection in older adults. Infect Dis Clin North Am. 2014 Mar;28(1):75-89.
  4. Das R, Perrelli E, Towle V, Van Ness PH, Juthani-Mehta M. Antimicrobial susceptibility of bacteria isolated from urine samples obtained from nursing home residents. Infect Control Hosp Epidemiol. 2009 Nov;30(11):1116-1119.
  5. Sundvall PD, Ulleryd P, Gunnarsson RK. Urine culture doubtful in determining etiology of diffuse symptoms among elderly individuals: a cross-sectional study of 32 nursing homes. BMC Fam Pract. 2011 May;12:36.
  6. National centre for disease control National treatment guidelines for antimicrobial use in infectious diseases. 2016. http://pbhealth.gov.in/AMR_guideline7001495889.pdf
  7. Naqvi SAR, Roohi S, Iqbal A, Sherazi TA, Zahoor AF, Imran M. Ciprofloxacin: from infection therapy to molecular imaging. Mol Biol Rep. 2018 Oct;45(5):1457-1468.
  8. Blaettler L, Mertz D, Frei R, Elzi L, Widmer A, Battegay M, et al. Secular trend and risk factors for antimicrobial resistance in Escherichia coli isolates in Switzerland 1997–2007. Infection. 2009 Dec;37(6):534-539.
  9. Sanchez GV, Master RN, Karlowsky JA, Bordon JM. In vitro antimicrobial resistance of urinary Escherichia coli isolates among US outpatients from 2000 to 2010. Antimicrob Agents Chemother. 2012 Apr;56(4):2181-2183.
  10. Santana TC, Pereira EM, Monteiro SG, Carmo MS, Turri RJ, Figueiredo PM. Prevalência e resistênciabacterianaaosagentesantimirobianos de primeiraescolhanasinfecções do tratourinário no município de São Luís-MA. Rev Patol Trop. 2012 Oct-Dec;4(4):409-418.
  11. Passadouro R, Fonseca R, Figueiredo F, Lopes A, Fernandes C. Evaluation of the antimicrobial susceptibility of communityacquired urinary tract infection. Acta Med Port. 2014 Nov- Dec;27(6):737-742.
  12. Reis AC, Santos SR, Souza SC, Saldanha MG, Pitanga TN, Oliveira RR. Ciprofloxacin resistance pattern among bacteria isolated from patients with community-acquired urinary tract infection. Rev Inst Med Trop Sao Paulo. 2016 Jul;58:53.
  13. Omigie O, Okoror L, Umolu P, Ikuuh G. Increasing resistance to quinolones: A four-year prospective study of urinary tract infection pathogens. Int J Gen Med 2009 Dec;2:171-175.
  14. Alakhali MK, Alzomor AK, Alavvudeen SS, Khan AN, Dawbaa S. Bacterial resistance of antibiotics antibiotics used in urinary tract infection. Asian J Pharm Clin Res 2013;6:87-91.
  15. Molina-López J, Aparicio-Ozores G, Ribas-Aparicio RM, Gavilanes-Parra S, Chávez-Berrocal ME, Hernández-Castro R, et al. Drug resistance, serotypes, and phylogenetic groups among uropathogenic Escherichia coli including O25-ST131 in Mexico City. J Infect Dev Ctries 2011 Dec; 5(12):840-849.
  16. Kandel SH, El-Hendy AA, Mohamed RR. Prevalence of quinolones resistance among patients with urinary tract infection at Menoufia. Menoufia Med J. 2014;27(2):440-446.
  17. Vellinga A, Murphy AW, Hanahoe B, Bennett K, Cormican M. A multilevel analysis of trimethoprim and ciprofloxacin prescribing and resistance of uropathogenic Escherichia coli in general practice. J Antimicrob Chemother. 2010 Jul;65(7):1514- 1520.
  18. Morgan DJ, Okeke IN, Laxminarayan R, Perencevich EN, Weisenberg S. Non-prescription antimicrobial use worldwide: a systematic review. Lancet Infect Dis. 2011 Sep;11(9):692-701.
  19. Dalhoff A. Global fluoroquinolone resistance epidemiology and implictions for clinical use. Interdisciplinary perspectives on infectious diseases. 2012;2012:1-37.
  20. Maron DF, Smith TJ, Nachman KE. Restrictions on antimicrobial use in food animal production: an international regulatory and economic survey. Global Health. 2013 Oct;9:48.
  21. Gupta K, Hooton TM, Naber KG, Wullt B, Colgan R, Miller LG, et al. Infectious Diseases Society of America; European Society for Microbiology and Infectious Diseases. International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: A 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases. Clin Infect Dis. 2011 Mar;52(5):e103-120.
  22. Machuca J, Briales A, Díaz-de-Alba P, Martínez-Martínez L, Pascual Á, Rodríguez-Martínez JM. Effect of the efflux pump QepA2 combined with chromosomally mediated mechanisms on quinolone resistance and bacterial fitness in Escherichia coli. J Antimicrob Chemother. 2015 Sep;70(9):2524-252 7.
  23. Redgrave LS, Sutton SB, Webber MA, Piddock LJ. Fluoroquinolone resistance: mechanisms, impact on bacteria, and role in evolutionary success. Trends Microbiol. 2014 Aug;22(8):438-445.
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.